Too many still dying of AIDS says MSF

Nsanje, Malawi: Simbazako, 19 years, undergoes radiography for tuberculosis in Nsanje district hospital, Malawi. MSF is working with medical teams in Nsanje district hospital to improve diagnosis and clinical care of AIDS, including imaging, laboratory and pharmacy support. Photographer: Luca Sola.
Nsanje, Malawi: Simbazako, 19 years, undergoes radiography for tuberculosis in Nsanje district hospital, Malawi. MSF is working with medical teams in Nsanje district hospital to improve diagnosis and clinical care of AIDS, including imaging, laboratory and pharmacy support. Photographer: Luca Sola.
Credit: Health24.com

While South Africa is doing much better than the Democratic Republic of Congo, Guinea and Malawi for example, death rates are still “shockingly” high, Dr Amir Shroufi, Deputy Medical Coordinator for MSF in the country, told Health-e News at the 9th International AIDS Society (IAS) Conference on HIV Science taking place in Paris this week.

With the incredible progress we’ve made in South Africa in terms of access to treatment, why on earth are so many people still dying?

“With the incredible progress we’ve made in South Africa in terms of access to treatment, why on earth are so many people still dying? Why are we missing opportunities to prevent those deaths?” Shroufi asked.

Up to 180 000 HIV deaths in SA

The Joint United Nations Programme on HIV/AIDS (UNAIDS) estimated that, in 2015, up to 180 000 deaths in South Africa were attributable to HIV.

A person living with HIV is defined as having AIDS or advanced HIV when their CD4 count – a measure of a person’s immunity – drops below 200.

According to Shroufi, in two of the districts MSF works with in South Africa (one in KwaZulu-Natal and one in the Western Cape) between 15 and 20 percent of patients living with HIV have AIDS.

“What’s killing people is tuberculosis (TB), Cryptococcal meningitis, a terrible fungal infection of the brain, and bacterial sepsis,” he said.

South Africa is not doing well with giving HIV patients preventative anti-TB drugs, implementing newer TB diagnostics or with access to new treatments for Cryptococcal meningitis.

New drug still not registered in SA

Flucytosine, a new drug used in combination with amphotericin, is still not registered in South Africa despite it being the ‘gold standard’ to treat Cryptococcal meningitis.

Shroufi said “it’s an awful disease with awful treatment” but this new drug makes therapy much more tolerable and effective.

“It is really urgent that this is registered soon and we are urging the South African government to make this a priority,” he said.

Meeting targets

“The 90-90-90 targets we’ve got at the moment are fantastic but there is nothing focusing on reducing deaths specifically.”

The UNAIDS targets are that, by 2020, 90 percent of people living with HIV should know their status, 90 percent of these people should be on ARVs and 90 percent of people on treatment should have suppressed viral loads.

Said Shroufi: “While those measures will reduce deaths over time, we’re calling for a shift in strategy from the government and donors because we need to address the main causes of deaths like TB, meningitis and other infections immediately.”

An edited version of this story was also published in Health24

Author

Free to Share

Creative Commons License

Republish our articles for free, online or in print, under a Creative Commons license.


Stay in the loop

We love that you love visiting our site. Our content is free, but to continue reading, please register.

Newsletter Subscription

Be in the know with our free weekly newsletter. We deliver a round-up of our top stories and insightful reads from across the web.

  • This field is for validation purposes and should be left unchanged.

Enable Notifications OK No thanks